No Clinically Significant Pharmacokinetic Interaction Between Ondansetron and THC
There is no documented clinically significant pharmacokinetic drug interaction between ondansetron (Zofran) and THC based on current evidence, though they may have overlapping sedative effects that warrant monitoring.
Pharmacokinetic Evidence
The FDA label for ondansetron explicitly states that it "does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system" 1. While ondansetron is metabolized by CYP3A4, CYP2D6, and CYP1A2 1, and THC inhibits some of these same enzymes (specifically CYP3A4, CYP2C9, and CYP2C19) 2, the 2024 ASCO guidelines note a "generally low probability of clinically relevant drug interactions with cannabis and/or cannabinoids" 2.
The multiplicity of metabolic pathways for ondansetron means that inhibition of one enzyme is likely compensated by others, resulting in "little change in overall rates of ondansetron elimination" 1. No dose adjustment for ondansetron is recommended when used with enzyme inhibitors 1.
Pharmacodynamic Considerations
The more relevant concern is additive sedative effects rather than metabolic interactions. Both agents can cause:
- Drowsiness and dizziness 2
- Sedation (THC causes sedation in 19% of cancer patients) 2
- Disorientation and confusion 2
These overlapping central nervous system effects may be enhanced when used together, particularly in older adults who are at higher risk for confusion and falls with cannabis use 2.
Clinical Context: Antiemetic Efficacy
Interestingly, ondansetron and THC work through different mechanisms and may have complementary antiemetic effects:
- Ondansetron blocks 5-HT3 receptors peripherally and centrally 1
- THC works through cannabinoid CB1 receptors 3
Animal studies demonstrate that combining ineffective doses of ondansetron (0.02 mg/kg) with THC (1.25 mg/kg) completely suppressed cisplatin-induced vomiting when neither was effective alone 4. However, for anticipatory nausea, THC was superior to ondansetron 5.
Practical Recommendations
When patients use both medications:
- Monitor for enhanced sedation, especially during initial co-administration
- Counsel patients to avoid driving for 5-8 hours after THC use (or longer depending on individual response) 2
- Use caution in older adults due to increased fall risk 2
- No ondansetron dose adjustment is needed based on pharmacokinetic considerations 1
- Space dosing if possible to minimize peak sedative effects occurring simultaneously
Important Caveats
The evidence base is limited. Most interaction data comes from animal models 6, 4, 5 or general statements about cannabinoid interactions 2. No human studies specifically examined ondansetron-THC interactions. The 2024 ASCO guidelines acknowledge that "clinicians will be unable to provide informed, scientifically supported answers" for most cannabis-drug interactions due to data paucity 2.
For cannabinoid hyperemesis syndrome specifically, ondansetron is listed as a treatment option 3, though haloperidol proved superior to ondansetron in one randomized trial 7.